| February 1 |
Eisai Announces Change in U.S. Submission Schedule for E7389 New
Drug Application |
| February 1 |
Biovail Receives Letter Related to 2003 Cardizem LA Launch
Activities from U.S. Attorney's Office |
| February 1 |
Vyteris Announces Redirection of Business Towards the Advancement
of Peptide Delivery |
| February 1 |
Roche Plans to Complete Ventana Offer on February 7th |
| February 1 |
Chiltern Announced Today That it has Acquired the Business of Drug
Development Solutions (DDS) |
| February 1 |
Teva Provides Update on Generic Protonix |
| February 1 |
Patheon Completes Sale of Niagara-Burlington Commercial
Manufacturing Business |
| February 1 |
FDA MedWatch- Chantix (varenicline)-Associated With Reports Of
Changes In Behavior, Agitation, Depressed Mood, Suicidal Ideation,
and Attempted/Completed Suicide |
| February 4 |
FDA Issues Public Health Advisory on Chantix |
| February 4 |
Amgen and Takeda Announce Exclusive Collaboration in Japan on up to
13 Amgen Clinical Candidates |
| February 4 |
Progen Expands Drug Development Pipeline Through Acquisition of
CellGate |
| February 4 |
Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement
for FLAP Inhibitor Program |
| February 4 |
Akela Pharma Receives Letter from the FDA Regarding its
Pre-clinical Toxicology Studies for Fentanyl Taifun |
| February 4 |
GE Healthcare to Acquire Whatman Plc: Recommended Acquisition at
270p Per Share in Cash |
| February 4 |
President's FY 2009 Budget Advances Food and Medical Product
Safety, and the Safety of FDA-Regulated Imports |
| February 4 |
FDA MedWatch- FDA MedWatch- Medtronic Inc. SnychroMed EL
Implantable Infusion Pump - Class I Recall |
| February 5 |
Vertical Search Engine Launches for the Pharmaceutical Industry |
| February 5 |
Watson to Distribute Alendronate Tablets |
| February 5 |
Senate Finance Chairman Baucus Comments on President’s FY2009
Budget |
| February 5 |
EMD Serono Canada Inc.-Raptiva: First Biologic Treatment for
Psoriasis to Receive Public Reimbursement in Two Atlantic Provinces |
| February 5 |
GSK Extends GeneGo License and Adds New Products |
| February 5 |
Affymax Affirms Progress with Takeda Collaboration |
| February 6 |
Canon Communications Acquires Pharmapack and Enters $9 Billion
European Market for Pharmaceutical Packaging |
| February 6 |
Neurogen Restructures to Focus Resources on Advancing Clinical
Programs |
| February 6 |
Biogen Idec Reports Full Year and Fourth Quarter 2007 Results |
| February 6 |
Alpharma Announces the Sale of Its Active Pharmaceutical
Ingredients Business to 3i for $395 Million in Cash |
| February 6 |
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive
Merger Agreement |
| February 6 |
Patients Appear to Be at Increased Risk of Adverse Events Within 3
Months After Stopping Clopidogrel Therapy for Acute Coronary
Syndrome |
| February 6 |
New Schizophrenia Treatment Now Available in Canada |
| February 6 |
Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License
Agreement With AstraZeneca |
| February 6 |
Methylgene Exercises Right to Opt-out of HDAC Neurodegenerative
Collaboration with EnVivo |
| February 6 |
Neurogen Restructures to Focus Resources on Advancing Clinical
Programs |
| February 6 |
Statement from the American Diabetes Association Related to ACCORD
Trial Announcement |
| February 6 |
For Safety, NHLBI Changes Intensive Blood Sugar Treatment Strategy
in Clinical Trial of Diabetes and Cardiovascular Disease |
| February 6 |
FDA Takes Action to Stop the Marketing of Unapproved Injectable
Drugs Containing Colchicine |
| February 7 |
Generic Fosamax Approved |
| February 7 |
Alcon's Fourth Quarter Sales Rise 20.0 Percent |
| February 7 |
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa
Long-Acting Injection (LAI) for Schizophrenia Treatment |
| February 7 |
PPD to Acquire InnoPharm Ltd. |
| February 7 |
Sen. Grassley Letter to Pharmaceutical Drug Maker About Notice of
Drug Trial Findings |
| February 7 |
GSK: Preliminary Results Announcement for the year ended 31st
December 2007 |
| February 7 |
Publicis Groupe Acquires La Vie est Belle |
| February 7 |
Merck Resolves Federal and State Investigations Related to Certain
Past Pricing And Certain Past Sales and Marketing Activities |
| February 7 |
Merck to Pay More than $650 Million to Resolve Claims of Fraudulent
Price Reporting and Kickbacks |
| February 8 |
Roche Purchases Shares in Tender Offer for Ventana |
| February 8 |
Neurogen Announces R&D Update |
| February 8 |
FDA Notifies Public of Adverse Reactions Linked to Botox Use |
| February 8 |
FDA issues an Early Communication about an Ongoing Safety Review
for Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc
(Botulinum toxin Type B) |
| February 11 |
Commenting on the U.S. Food and Drug Administration (FDA) Early
Communication, Allergan Clarifies FDA's Inquiry Relates Primarily
to High Dose Medical Uses of Botox, Rather Than Botox Cosmetic for
Aesthetic Use |
| February 11 |
Bayer HealthCare Affiliate Medrad and Possis Medical Sign
Definitive Merger Agreement |
| February 11 |
CytRx Receives FDA Correspondence Regarding Phase IIb Arimoclomol
Clinical Trial in ALS |
| February 11 |
Convera and Canon Communications Launch PharmaLiveSearch.com |
| February 11 |
ICON Announces The Acquisition Of Healthcare Discoveries Inc |
| February 11 |
Baxter's Multiple-Dose Vial Heparin Linked to Severe Allergic
Reactions |
| February 12 |
Schering-Plough Reports Financial Results for 2007 Fourth Quarter,
Full Year |
| February 12 |
Cell Signaling Technology Announces Continued Collaboration with
AstraZeneca to Provide CST's PhosphoScan Platform for Kinase
Inhibitor Proteomic Profiling |
| February 12 |
Nektar Announces Restructuring to Complete Its Transition to a
Therapeutics Drug Development Organization |
| February 12 |
Dana-Farber, Merck &Co. Inc. Enter Agreement to Create 'Team''
Approach to Cancer Drug Development |
| February 12 |
Boston Scientific Announces Court Decision |
| February 12 |
Teva Reports Fourth Quarter and Full Year 2007 Results |
| February 12 |
Dyax Corp. Enters Into Antibody Agreements with Sanofi-aventis for
the Fully Human Monoclonal Antibody DX-2240 and Phage Display
Technology |
| February 12 |
Intertek Acquires BioClin Laboratory in Ireland |
| February 12 |
American Association of Clinical Endocrinologists and North
American Menopause Society Fail to Disclose Financial Ties to Wyeth
Pharmaceuticals |
| February 12 |
Altor BioScience In-Licenses Tissue Factor Antagonists from
Genentech |
| February 12 |
Sanofi-Aventis: 2007 Fourth-Quarter and Full-Year Net Sales |
| February 12 |
DAS Division of Omnicom Acquires Direct Marketing Shop Kern and
Aligns With Rapp Collins Worldwide |
| February 12 |
Nastech Pharmaceutical Company Implements Additional Workforce
Reduction as Part of Previously Announced Corporate Restructuring |
| February 12 |
PriCara Recalls 25 mcg/hr Duragesic (fentanyl transdermal system)
CII Pain Patches |
| February 13 |
Cellegy Pharmaceuticals Announces Signing of Definitive Merger
Agreement |
| February 13 |
More Americans Are Using More Prescription Drugs |
| February 13 |
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year |
| February 13 |
DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce
Consummation of Merger |
| February 13 |
Reps. Dingell, Stupak Request Additional Information on Enhance
Trial |
| February 13 |
Cellartis Enters Into a Research Collaboration with Pfizer to
Develop a Screening System for Detection of Human Toxicity |
| February 13 |
Jobson Medical Information LLC Acquires Gerber Communications and
Practice Advancement Associates |
| February 14 |
Cephalon Statement on Federal Trade Commission Action Regarding
Provigil Patent Settlements |
| February 14 |
West Concludes Agreement with Nektar |
| February 14 |
Sanofi Pasteur and Statens Serum Institut Team Up Against
Tuberculosis |
| February 14 |
Missing Price Information Hampers Usefulness of State Prescription
Drug Web Sites |
| February 14 |
FTC Sues Cephalon, Inc. for Unlawfully Blocking Sale of Lower-Cost
Generic Versions of Branded Drug Until 2012 |
| February 14 |
AstraZeneca and Nomura Phase4 Ventures Announce Creation of New
Company “Albireo” |
| February 14 |
Physicians Expect to Decrease First- and Second- Line Use of
Vytorin in Wake of ENHANCE Trial Results, According to Study by GfK
Market Measures |
| February 14 |
Watson Pharmaceuticals Announces FDA Inspection of Florida
Facilities |
| February 14 |
GSK Launches New Website to Help Employers Lower Costs and Improve
the Health of Workers |
| February 14 |
TorreyPines Therapeutics Announces Strategic Plan with Focus on
Clinical Development Activities to Maximize Value of Versatile Lead
Compounds |
| February 14 |
Genedata and Roche Join Forces in Proteomics Process |
| February 14 |
Pennsylvania Attorney General Corbett Announces Multi-State
Settlement With Caremark |
| February 15 |
Icagen Announces Closing of Investment by Pfizer |
| February 15 |
Risk of Peripheral Neuropathy with Sebivo (telbivudine) |
| February 15 |
Record Operating Results for Solvay in 2007 of EUR 1.2 billion, up
9% from 2006(+24% in the 4th quarter) |
| February 15 |
Vaccinex Antibody Licensed to GlaxoSmithKline |
| February 15 |
Announcement in Relation to the Movement in the ClinPhone Share
Price |
| February 15 |
FDA Proposes Guidance for Dissemination of Information on
Unapproved Uses of Medical Products |
| February 15 |
KMR Group Assesses Clinical Productivity In Biopharmaceutical
Industry |
| February 19 |
Memory Pharmaceuticals & Roche Expand Development Program for
MEM 3454 in Schizophrenia |
| February 19 |
Roche Completes Tender Offer for Ventana Shares |
| February 19 |
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to
GlaxoSmithKline for up to $44 Million Plus Royalties |
| February 19 |
Actavis Recalls Certain Fentanyl Patches in the US as Precaution |
| February 19 |
ClinPhone: Statement re: Share Price Movement |
| February 19 |
Takeda Discontinues Development of Matuzumab |
| February 19 |
Merck Triples 2007 Profit After Tax to EUR 3.5 Billion |
| February 19 |
Wyeth Wins Thimerosal-Autism Case in Maryland Court |
| February 20 |
Oxford Biomedica Announces Data Safety Monitoring Board
Recommendation to Continue Trovax Phase III Trist Study |
| February 20 |
Sunesis Pharmaceuticals Announces Milestone Payment from
Inflammation Collaboration |
| February 20 |
pSivida Receives First R&D Payments from Pfizer |
| February 20 |
CSL: Interim Result, Strong Profit Growth From Operations, Up 36%
to $349 Million |
| February 20 |
Pfizer to Acquire Encysive Pharmaceuticals |
| February 20 |
Vernalis Announces Management Changes |
| February 20 |
Genstruct Announces New Collaboration with Pfizer in Drug Safety |
| February 21 |
Shire: Excellent Performance Across All Areas of the Business and
Accelerating New Product Sales Drive Revenue Growth of 36% |
| February 21 |
Millipore Corporation Signs License Agreement with Bayer HealthCare
AG |
| February 21 |
I-many Closes Acquisition of GHX Pharma Solutions Data Validation
Assets |
| February 21 |
Merck to Seek Appellate Review of Class Certification Decision in
Vioxx Proceedings in Saskatchewan |
| February 21 |
Genmab and PDL BioPharma Sign Purchase Agreement for Antibody
Manufacturing Facility |
| February 21 |
Appellate Court in the Netherlands Upholds Basic Lipitor Patent,
Prevents Launch of Ranbaxy Product before November 2011 |
| February 21 |
MorphoSys and Astellas Extend Alliance for Use of HuCAL GOLD to
Develop Novel Antibody Therapies |
| February 21 |
Entelos, Inc. and PDL Biopharma Enter Silico Research Agreement |
| February 21 |
AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama
Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court
of Montgomery, Alabama |
| February 22 |
FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug,
prasugrel |
| February 22 |
Reps. Dingell, Stupak Consider Changing Law Over Heparin Failures |
| February 22 |
BMJ: Investigation Reveals "Invisible Influence" of Sponsors in
Medical Education |
| February 25 |
BioAlliance Pharma to Pursue Its Strategy for the Targeted
Acquisition of Complementary Products Following the Announcement of
the of Immtech Pharmaceuticals' Pafuramidine Program |
| February 25 |
Eucreas, a single-tablet combination of Galvus and metformin, set
for launch in first EU countries as new treatment for type 2
diabetes |
| February 25 |
GPC Biotech Announces Corporate Restructuring and Provides Pipeline
Update |
| February 25 |
Strativa Pharmaceuticals, a Division of Par Pharmaceutical,
Announces the Discontinuation of the Development Program for
Pafuramidine |
| February 25 |
Addex Achieves First Milestone in Parkinson's Disease Collaboration
with Merck & Co., Inc. |
| February 25 |
Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr.
Robert Jarvik |
| February 26 |
Genentech Receives Notification of Rejection of Cabilly Patent
Claims From Reexamination Process |
| February 26 |
Reps. Dingell, Stupak Comment on Pfizer Decision to Pull Lipitor
Ads Featuring Dr. Jarvik |
| February 26 |
GlaxoSmithKline and Theravance Announce Expansion of the Horizon
Programme with Start of Large Phase 2B Study of LABA in COPD
Patients |
| February 26 |
Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals |
| February 26 |
Who Benefits from Antidepressants? US Health Inequities |
| February 26 |
FDA MedWatch - Avandia (rosiglitazone maleate): new Medication
Guide issued |
| February 26 |
Statement of Robert Jarvik, MD, President and CEO of Jarvik Heart,
Inc. Regarding the Lipitor DTC Advertisements |
| February 27 |
AstraZeneca Provides Update On Recentin Clinical Development
Programme |
| February 27 |
Sanofi Pasteur MSD Welcomes Sweden's Decision to Recommend and Fund
Human Papillomavirus Vaccination for School Girls |
| February 27 |
Abbott, Genentech and WEHI Collaborate to Research and Develop New
Anti-Cancer Drugs |
| February 27 |
Receptor Logic Teams with Sanofi Pasteur to Develop T Cell Receptor
Mimics (TCRm) for Vaccine Research |
| February 27 |
Switching Medications, Adding Psychotherapy May Help Teens Whose
Initial Medication for Depression is Ineffective |
| February 27 |
Ortho Biotech Statement On JAMA Publication Regarding
Erythropoiesis-Stimulating Agents |
| February 27 |
Agents Used for Treatment of Anemia Associated with Increased Risk
of Blood Clots, Death in Patients with Cancer |
| February 27 |
GlaxoSmithKline Statement: Public Library of Science Medicine
Article on Antidepressant Medicines |
| February 27 |
Bruker Corporation Announces Closing of the Acquisition of the
Bruker BioSpin Group |
| February 27 |
FDA MedWatch - Tysabri (natalizumab) - Reports Of Clinically
Significant Liver Injury |
| February 28 |
AstraZeneca Provides An Update on the Status of its Arrangements
With Merck & Co., Inc. |
| February 28 |
Wenning: 2007 Was Bayer’s Most Successful Year to Date |
| February 28 |
Merck Retains Interest in AstraZeneca LP Products |
| February 28 |
Novartis and Sony Pictures Television International's Latin
American Advertising Sales Group Launch Partnership to Create
Multi-Media Platform for Breast Cancer Awareness, Detection, and
Treatment in Latin America |
| February 28 |
Support for the Physician Payments Sunshine Act, S.2029 |
| February 28 |
King Pharmaceuticals Reports Year-End and Fourth-Quarter 2007
Financial Results |
| February 28 |
Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the
Netherlands, Company Notes That Ruling Has No Commercial Impact |
| February 28 |
Mylan Announces Amendment to Bystolic (Nebivolol) Agreement |
| February 29 |
Baxter to Proceed With Recall of Remaining Heparin Sodium Vial
Products |
| February 29 |
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay
Pharmaceuticals for Bifeprunox and Other Compounds |
| February 29 |
Generic Drugs Slow Rise in Prescription Drug Costs, Saving $5.2
Billion in 2007 |
| February 29 |
Interpublic Announces Fourth Quarter and Full-Year 2007 Results |
| February 29 |
Pharmacyclics Realigns to Focus on Advancing Expanded Pipeline of
Promising Product Candidates |
| February 29 |
QPS Closes Acquisition of Bio-Kinetic Clinical Applications |
| February 29 |
New Study of Targeted Therapies for Breast Cancer Establishes Model
for Global Clinical Trials |
